And the answer, as always, depends on individual situation
In a statement, the Danish company said the move would help to address "access barriers" to the medicines and "make it easier and more affordable for people in the US to get authentic, FDA-approved Wegovy and Ozempic in the way that best fits their lives." There's little doubt that one of the reasons for the move will be to try to keep pace with arch-rival Eli Lilly in the market for incretin-based therapies for obesity and T2D, particularly the strong growth of Lilly's dual GIP/GLP-1 agonist tirzepatide, whose growth rate is outstripping Novo Nordisk's products
The European Commission also approved the . - , which Novo Nordisk says demonstrated %* in its #clinical development programme
Pratley et al., 2010)
Tests tolerability in the presence of greater comorbidity and provides interim safety data ahead of the longer cardiovascular outcomes trial
Puede que suene a una utopa, pero todos pueden llevar una vida ms saludable, lo cual mejorar las cosas para la sociedad en su conjunto.